|
Cell Biochemistry Martinsried |
= external links
gene expression profiling
(L1)
using "Lymphochip" arrays (7399 gene spots) has permitted to
characterize the additional type3 large B-cell lymphoma by
an hierarchical clustering algorithm. A method was developed
to predict the likelihood of survival after chemotherapy for
diffuse large B-cell lymphoma. This predictor of prognosis and the
international prognostic index (IPI) are independent prognostic
indicators.
2. Goal:
Predictors of prognosis are patient group
oriented and valuable for therapeutic patient stratification.
They are, however, not informative as outcome predictors
for individual patients prior to an envisaged chemotherapy.
- The goal of a study on the above
data
is directed towards the pretherapeutic identification (>95% correct)
of high risk DLBCL patients by a
data sieving algorithm
3. Results: Present results suggest that predictive identification for individual patients are possible and that predictive (fig.1) and prognostic (fig.2) data patterns are different although a certain number of lymphocyte associated parameters are selected in both cases. Eight of the differentially expressed genes in the predictive pattern concern genes of unknown function. This seems of particular interest for further studies on gene regulation in DLBCL.
4. Conclusion:
The classification of the reported data suggest that individualized
pretherapeutic risk assessment for patient survival is possible
(L3).
Literature References:
L1
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI,
Gascoyne RD, Müller-Hermelink HK, Smeland EB, Staudt LM:
The use of molecular profiling to predict survival after
chemotherapy for diffuse large B-cell lymphoma.
NEJM 346:1937-47(2002)
L2 Ando T, Katayama M, Seto M, Kobayashi T, Honda H:
Selection of causal genes sets from transcriptional profiling
by FNN modeling and prediction of lymphoma outcome.
Genome Informatics 13:278-279(2002)
L3 Valet G, Höffkes HG, Repp R, Gramatzki M, Ehninger G:
Perspectives in clinical and medical cytomics: Individualized
pretherapeutic risk assessment for diffuse large-B-cell lymphoma and
acute mayeloid leukemia (AML) patients.
JBRHA 16:306-7 (2002)
1965-2006:
Max-Planck-Institut für Biochemie, Am Klopferspitz 18a,
D-82152 Martinsried, Germany
© 2026 G.Valet
Last update: Apr 14,2003
First display: Apr 02,2003